General Public
About TrialNet Studies
Joining TrialNet Studies
Health Care Professionals
Research Collaborators
Media
General Public
About TrialNet Studies
Joining TrialNet Studies
Health Care Professionals
Research Collaborators
Media
Type 1 Diabetes TrialNet is a NIH-sponsored clinical trials network which conducts studies designed to evaluate new approaches to prevent or ameliorate T1D specifically by interdicting the T1D disease process. These include interventions designed to decrease β-cell destruction and/or enhance β-cell survival.
Studies are conducted in non-diabetic persons at risk of T1D in an effort to delay the development of T1D as a clinical disease; or (if initiated prior to appearance of autoimmunity) in an effort to delay the appearance of autoimmunity; or in individuals with T1D who are either newly diagnosed or have evidence of sustained beta cell function. Studies may include long-term follow-up of subjects developing T1D.
The TrialNet network will also support natural history and genetics studies in populations screened for or enrolled in studies conducted by the TrialNet study group. In addition, TrialNet will evaluate methodologies that enhance the conduct of clinical trials interdicting the T1D disease process.
Approved May 2005 by Steering Committee, Type 1 Diabetes TrialNet, May 2005, Alexandria, VA